Printer Friendly

Elanco to divest EEA and UK rights to Drontal and Profender.

M2 PHARMA-February 13, 2020-Elanco to divest EEA and UK rights to Drontal and Profender


Animal health company Elanco Animal Health Incorporated (NYSE: ELAN) said on Wednesday that it has agreed to sell the European Economic Area and UK rights to the Drontal and Profender product families from Bayer AG's (ETR:BAYN) animal health business.

French pharmaceutical company Vetoquinol SA (EURONEXT:VETO) will pay USD140m for the rights in an all-cash deal subject to customary post-closing adjustments.

Drontal and Profender are both de-wormers for dogs and cats.

Elanco stated that the sale of the rights to Drontal and Profender in the European Economic Area and the UK further advances its efforts to gain European Commission clearance for the acquisition of Bayer AG's global animal health business.

Closing of the transaction with Vetoquinol is contingent on Elanco closing its transaction with Bayer, as well as other customary closing conditions.

((Comments on this story may be sent to

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Feb 13, 2020
Previous Article:Q-linea announces global, exclusive partnership with Thermo Fisher Scientific for commercialisation of ASTar.
Next Article:Synspira Therapeutics signs contract with Cystic Fibrosis Foundation.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters